Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply

被引：0
|
作者：
Vasudevan, Abhinav [1 ,2 ,4 ]
Con, Danny [3 ]
van Langenberg, Daniel R. [1 ,2 ]
机构：
[1] Eastern Hlth, Dept Gastroenterol & Hepatol, Box Hill, Australia
[2] Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia
[3] Austin Hosp, Dept Gastroenterol, Melbourne, Australia
[4] Box Hill Hosp, Dept Gastroenterol & Hepatol, Eastern Hlth, 8 Arnold St, Box Hill, Vic 3128, Australia
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2024年 / 59卷 / 06期
关键词：
D O I：
10.1111/apt.17895
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LINKED CONTENT This article is linked to Vasudevan et al papers. To view these articles, visit and
引用
收藏
页码：794 / 794
页数：1
相关论文
共 50 条
  • [1] Towards optimal thiopurine therapy for inflammatory bowel disease
    van Liere, Elsa L. S. A.
    de Boer, Nanne K. H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (06) : 792 - 793
  • [2] Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply
    Chapman, Thomas P.
    Frias Gomes, Catarina
    Louis, Edouard
    Colombel, Jean-Frederic
    Satsangi, Jack
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (10) : 1621 - 1621
  • [3] Letter: diagnostic delay in inflammatory bowel disease-Authors' reply
    Pollok, Richard
    Baillie, Samantha
    Jayasooriya, Nishani
    Blackwell, Jonathan
    Petersen, Irene
    Bottle, Alex
    Saxena, Sonia
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (10) : 1205 - 1206
  • [4] Editorial: treating strictures in inflammatory bowel disease-authors' reply
    Rieder, Florian
    Feagan, Brian G.
    Jairath, Vipul
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (11-12) : 1313 - 1314
  • [5] Letter: pancreatic involvement in inflammatory bowel disease-authors' reply
    Massironi, Sara
    Vigano, Chiara
    Danese, Silvio
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (02) : 371 - 371
  • [6] Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease-authors' reply
    Friedman, A. B.
    Sparrow, M. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (01) : 98 - 99
  • [7] Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply
    Fairbrass, Keeley M.
    Hamlin, P. John
    Gracie, David J.
    Ford, Alexander C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (08) : 1302 - 1303
  • [8] Letter: off-label use of hyperbaric oxygen therapy in inflammatory bowel disease-Authors' reply
    Simsek, Melek
    de Boer, Nanne K. H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (01) : 216 - 217
  • [9] Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply
    Christensen, B.
    Gibson, P. R.
    Rubin, D. T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (10) : 1423 - 1424
  • [10] Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with inflammatory bowel disease-authors' reply
    Rosiou, Konstantina
    Selinger, Christian P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (05) : 898 - 899
12345